Videos

Neeraj Agarwal, MD, discusses how the prostate-specific antigen responses correlate with survival outcomes in 2 phase 3 trials of apalutamide in patients with advanced prostate cancer.

Dr Mazyar Shadman and Dr Brian T. Hill focus on CD19 being targeted in monoclonal antibody therapy options for relapsed/refractory diffuse large B-cell lymphoma, specifically tafasitamab.

Drs Shadman and Hill discuss using CD19 as a targeted therapy option in CAR T cell therapy for relapsed/refractory diffuse large B-cell lymphoma.

An oncologist discusses the future of myelodysplastic syndrome, including upcoming studies and potential treatments.

Dr. Naval Daver provides insight on the emerging first-line treatment options for high-risk myelodysplastic syndrome and breaks down clinical trial data.

An expert details the treatment options for high-risk myelodysplastic syndrome.

Naval Daver, MD, illustrates the goals of treatment and treatment options for low-risk myelodysplastic syndrome.

A key opinion leader describes how myelodysplastic syndrome is diagnosed, the typical presenting symptoms, and the methods of risk assessment.

Naval Daver, MD, explains myelodysplastic syndrome, including risk factors and potential complications.

Jesús García-Foncillas, MD, PhD, discusses the rationale behind comparing the efficacy of larotrectinib and entrectinib head-to-head in patients with metastatic solid tumors with neurotrophic gene fusions.

Chung-Han Lee, MD, PhD, discusses the phase 2 KEYNOTE-B61 trial of pembrolizumab plus lenvatinib in patients with non–clear cell renal cell carcinoma.

Theodore W. Laetsch, MD, an attending physician at the Cancer Center at Children’s Hospital of Philadelphia, discusses the efficacy of larotrectinib in patients with TRK-fusion cancers.

Michael D. Chuong, MD, a radiation oncologist and medical director of Proton Therapy at Miami Cancer Institute, Baptist Health South Florida, discusses the benefits of MRI-guided radiation therapy in pancreatic cancer.

Limitations of current therapies available for the prevention and management of chemotherapy-induced neutropenia.

Current mitigation and management strategies for chemotherapy-induced neutropenia.

John Diaz, MD, discusses the current results of the phase 1 trial of STRO-002, a novel FRα-targeting antibody-drug conjugate, in patients with ovarian cancer.

The experts delve further into treatment methods for relapsed/refractory diffuse large B-cell lymphoma, particular for transplant-eligible and -ineligible patients.

Mazyar Shadman, MD, MPH, and Brian T. Hill, MD, PhD, explain the intricacies of the diffuse large B-cell lymphoma treatment landscape.

Corey S. Cutler, MD, MPH, FRCPC, discusses the trial of belumosudil in patients with chronic graft-vs-host disease.

John Marshall, MD, speaks on regorafenib sequencing and relays his thoughts on the future of treatment for metastatic colorectal cancer.

Dr Marshall discusses the impact regorafenib has had in the treatment of metastatic colorectal cancer and describes data from the CORRECT and ReDOS clinical trials.

A gastrointestinal cancers expert describes monitoring strategies for progression of metastatic colorectal cancer.

Dr Marshall explains the different frontline treatment options for metastatic colorectal cancer, as well as maintenance therapy.

John Marshall, MD, provides an overview of the colorectal cancer landscape.

John Mascarenhas, MD, and Ruben Mesa, MD, share insights on the evolving treatment landscape of myelofibrosis.

Neal Shore, MD, FACS, discusses the use of metastases-free survival as the primary end point in the ARAMIS trial, which looked at darolutamide in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).

Neal Shore, MD, FACS, explains the relationship between the use of darolutamide and control of urinary and bowel adverse events, as observed in an analysis of the phase 3 ARAMIS clinical trial.

Ramez Eskander, MD, summarizes the current status of ovarian cancer treatment and reviews unanswered questions and future directions.

Dr Ramez Eskander shares his insights on considerations for selecting appropriate PARP inhibitor therapy for patients based on molecular testing and other factors.

An expert in ovarian cancer discusses the mechanism of action of PARP inhibitors in treating advanced ovarian cancer and comments on tolerability profiles of available agents.